{"aliases":[{"type":"CodeName","name":"MK-3222"},{"type":"Synonym","name":"immunoglobulin G1, anti-(human interleukin 23) (human-Mus musculus monoclonal heavy chain), disulfide with human-Mus musculus monoclonal light chain, dimer"},{"type":"CASRegistryName","name":"1326244-10-3"},{"type":"USBrandName","name":"Iluyma"},{"type":"ChemicalStructureName","name":"immunoglobulin G1 anti-(human interleukin-23) humanized mouse monoclonal gamma1 heavy chain (219-214')-disulfide with humanized mouse monoclonal kappa light chain dimer (225-225'':228-228'')-bisdisulfide"}],"definition":{"html":"A humanized monoclonal antibody directed against the p19 protein subunit of interleukin-23 (IL-23), with immunomodulating activity. Upon subcutaneous administration, tildrakizumab targets and binds to the p19 subunit of IL-23, thereby neutralizing IL-23 and preventing the binding of IL-23 to its receptor. This inhibits IL-23-mediated signaling and inhibits differentiation of CD4 positive T cells into Th1 and Th17 cells. This prevents Th1- and Th17-mediated responses and cytokine production. This may prevent or reduce symptoms and severity of graft versus host disease (GVHD). IL-23, a pro-inflammatory cytokine that play a key role in the regulation of the immune system, is upregulated in immune-mediated inflammatory disorders. Both Th1 and Th17 cells play a crucial role in GVHD.","text":"A humanized monoclonal antibody directed against the p19 protein subunit of interleukin-23 (IL-23), with immunomodulating activity. Upon subcutaneous administration, tildrakizumab targets and binds to the p19 subunit of IL-23, thereby neutralizing IL-23 and preventing the binding of IL-23 to its receptor. This inhibits IL-23-mediated signaling and inhibits differentiation of CD4 positive T cells into Th1 and Th17 cells. This prevents Th1- and Th17-mediated responses and cytokine production. This may prevent or reduce symptoms and severity of graft versus host disease (GVHD). IL-23, a pro-inflammatory cytokine that play a key role in the regulation of the immune system, is upregulated in immune-mediated inflammatory disorders. Both Th1 and Th17 cells play a crucial role in GVHD."},"drugInfoSummaryLink":null,"nciConceptId":"C152627","nciConceptName":"Tildrakizumab","termId":799836,"name":"tildrakizumab","firstLetter":"t","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"tildrakizumab"}